Specifically, the IHC staining of CD8(+) T cells in the tumor tissue showed that, while there was no significant increase in CD8(+) T cell expression in the BJIKT monotherapy or pembrolizumab monotherapy groups compared to the control group, a significant increase was observed in the combination group. This evidence concerns the gene CD8A and neoplasm.